5,924 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Nomura Holdings Inc.

Nomura Holdings Inc. acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,924 shares of the biotechnology company's stock, valued at approximately $2,090,000.

Other institutional investors have also bought and sold shares of the company. Park Avenue Securities LLC raised its position in shares of United Therapeutics by 18.4% during the 4th quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock worth $922,000 after buying an additional 407 shares in the last quarter. USA Financial Formulas boosted its holdings in shares of United Therapeutics by 856.0% in the fourth quarter. USA Financial Formulas now owns 870 shares of the biotechnology company's stock valued at $307,000 after acquiring an additional 779 shares in the last quarter. Merit Financial Group LLC increased its stake in shares of United Therapeutics by 36.6% during the fourth quarter. Merit Financial Group LLC now owns 3,463 shares of the biotechnology company's stock valued at $1,222,000 after acquiring an additional 927 shares during the period. HB Wealth Management LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $376,000. Finally, UMB Bank n.a. raised its holdings in United Therapeutics by 4.9% during the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after purchasing an additional 51 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at $497,962.50. This represents a 69.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,500 shares of company stock valued at $17,054,780 over the last three months. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Stock Down 0.5%

Shares of NASDAQ UTHR traded down $1.42 during mid-day trading on Thursday, hitting $308.27. 70,266 shares of the company traded hands, compared to its average volume of 442,307. The business has a 50 day moving average of $300.05 and a two-hundred day moving average of $339.31. The stock has a market capitalization of $13.90 billion, a price-to-earnings ratio of 13.58, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 1 year low of $264.33 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $6.17 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of research reports. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a report on Monday, April 21st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.